ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2017.2.7935Keywords:
ankylosing spondylitis, endothelial dysfunction, cardiovascular risk.Abstract
Background. Ankylosing spondylitis is a disease that induces damage to the musculoskeletal system. Mortality rate among patients with AS is in 1.5 times higher than the population level. It is caused by cardiovascular disease and chronic renal failure.
Objective. The research was aimed to study the prevalence of endothelial dysfunction and to establish its dependence on the factors of cardiovascular risk in patients with AS.
Methods. 104 patients with ankylosing spondylitis (AS) were examined using standard diagnostic methods, such as disease activity, lipidogram, ultrasound of the carotid artery intima media, and endothelium vasodilatation in response to reactive hyperaemia was evaluated. Clinical activity of the disease was determined using the disease activity index BASDAI, BASFI functional index, index BASMI metrology, ASQoL quality of life. To estimate the 10-year risk of cardiovascular disease, the QRISK scale was used.
Results. Endothelial dysfunction (ED) was found in 47% cases. It was established that in the patients with ED<10% the incidence of LPL>1.7 mg/L, HDL-C<1.0 mmol/L, TIM thickening>0.9 mm was higher than in the patients with ED>10%. In this group of patients, significant duration of the disease and essential differences in their progress in terms of VAS, CRP, ESR, index activity and functional disorders were revealed.
Conclusions. The problem of CVD in patients with AS may be caused by systemic inflammatory disease associated with the development of endothelial dysfunction and increased levels of atherogenic lipids.
References
Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007. 369:1379–1390.
Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondy¬litis. Ann Rheum Dis. 2011;70(6):896–904.
Brown MA, Kenna T, Wordsworth BP (2016) Genetics of ankylosing spondylitis-insights into pathogenesis. Nat Rev Rheumatol.12:81–91.
Chen HA, Chen СH, Liao HT, et al. Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol. 2012;39(5):1013–8.
Erre GL, Sanna P, Zinellu A, Ponchietti A, Fenu P, Sotgia S, Carru C, et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol. 2001;30:21–27.
Heeneman S. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol. 2007. 19:358–362.
Kumar A, Falodia SK, Shankar S, Grover R, Marwaha V, Aneja R, Srivastava K, Das N. Assessment of serum nitrite as biomarker of disease activity in ankylosing spondylitis. Indian J Rheumatology. 2009;4:47–50.
McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:S124–S126.
Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115.
Poddubnyĭ DA, Rebrov AP. Endothelial dysfunction in patients with Bechterew’s disease (ankylosing spondylitis). Klin Med (Mosk). 2007;85:66–69.
Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade. Clin Rheumatol. 2010;29:763–770.
Taurog JD, Chhabbra A, Colbert RA. Axial spondyloarthritis and ankylosing spondylitis. New Engl J Med. 2016;26:2563–2574.
Unified clinical protocols of primary, emergency and secondary (specialized) medical help: Arterial hypertension. http://www.moz.gov.ua/ua/portal/allresources/. Accessed 2016.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
